Zydena (udenafil)
Zydena is the original udenafil brand from Dong-A Pharmaceutical in South Korea. Learn what udenafil is and where it is used.
- Active ingredient
- Udenafil
- Form
- Tablet
- Company
- Dong-A Pharmaceutical (South Korea)
Zydena is the original brand of udenafil, a PDE5 inhibitor developed and marketed by Dong-A Pharmaceutical in South Korea. A 2020 review describes it as available for erectile dysfunction in South Korea only.
How udenafil compares
Udenafil reaches peak levels within about 1 to 1.5 hours and has a half-life of 11 to 13 hours, between sildenafil and tadalafil. Korean studies have tested it both on demand and as a daily dose, including in men taking blood-pressure medicines.
Outside Korea
Udenafil is not authorized by the EMA, MHRA or US FDA. An Indian udenafil brand, Zudena, is listed by Sunrise Remedies.
Product record
- Company
- Dong-A Pharmaceutical (South Korea)
- Strengths
- Udenafil 100 and 200 mg (clinical trial doses)
- Market
- South Korea (Dong-A Pharmaceutical)
- Treatment area
- Erectile dysfunction (ED)
- Information checked
- 3 October 2026
Published research describes this product; it is not authorized in the EU, UK or US.
About udenafil
Udenafil is a PDE5 inhibitor developed in South Korea. It reaches peak levels in about 1 to 1.5 hours and lasts longer than sildenafil. It is not authorized in the EU, UK or US, so English-language leaflets rarely cover it.
Using a PDE5 inhibitor safely
Never take a PDE5 inhibitor with nitrates, recreational nitrites (“poppers”) or riociguat, and do not combine two ED medicines. Seek urgent medical help for chest pain, an erection lasting more than four hours, or sudden loss of vision or hearing.
Common side effects include headache, flushing, indigestion and a blocked nose.
Sources
Checked .
- The Use of Vasoactive Drugs in the Treatment of Male Erectile Dysfunction: Current Concepts (J Clin Med, 2020) — Europe PMC
- Udenafil: efficacy and tolerability in the management of erectile dysfunction (Ther Adv Urol, 2013) — Europe PMC
- The efficacy and safety of udenafil [Zydena] in hypertensive men (J Sex Med, 2009) — Europe PMC